Literature DB >> 20561621

Effective bowel cleansing before colonoscopy: a randomized study of split-dosage versus non-split dosage regimens of high-volume versus low-volume polyethylene glycol solutions.

Riccardo Marmo1, Gianluca Rotondano, Giovanni Riccio, Armando Marone, Maria Antonia Bianco, Italo Stroppa, Anna Caruso, Nicola Pandolfo, Stefano Sansone, Elena Gregorio, Giuseppe D'Alvano, Nicoletta Procaccio, Pina Capo, Clelia Marmo, Livio Cipolletta.   

Abstract

BACKGROUND: Adequate bowel cleansing is essential for a high-quality, effective, and safe colonoscopy.
OBJECTIVES: To evaluate the degree of colon cleansing comparing split-dosage versus non-split-dosage intake of two different polyethylene glycol (PEG) volumes (low-volume PEG + ascorbic acid vs standard-volume PEG-electrolyte solution) and to identify predictors of poor bowel cleansing.
DESIGN: Single-blind, active control, randomized study.
SETTING: Tertiary-care institutions in Italy. PATIENTS: This study involved adult patients undergoing elective colonoscopy. INTERVENTION: Colonoscopy with different bowel preparation methods. MAIN OUTCOME MEASUREMENTS: Degree of bowel cleansing.
RESULTS: We randomized 895 patients, and 868 patients were finally included in intention-to-treat (ITT) analysis. Overall compliance was excellent (97%) for both preparation methods. No difference in tolerability was recorded. Palatability was superior with low volume compared with high volume (acceptable or good 58% vs 51%, respectively, P < .005), independently of intake schedule. PEG plus ascorbic acid produced the same degree of cleansing as standard-volume PEG-electrolyte solution (77% vs 73.4%, respectively, within the split-dosage group and 41.7% vs 44.3%, respectively, within the non-split-dosage group). Independently of PEG volumes, the split-dosage regimen produced markedly superior cleansing results over the same-day method (good/excellent 327/435, 75.2% vs 186/433, 43.0%, P = .00001). Maximum cleansing was observed in colonoscopies performed within 8 hours from the last fluid intake versus over 8 hours from the last fluid intake (P < .001). The degree of bowel cleansing affected both cecal intubation (failed intubation 11.7% with fair/poor preparation vs 1.2% with good/excellent preparation, P = .00001) and polyp detection rates (12.2% with fair/poor vs 24.6% with good/excellent preparation, P = .001). Aborted procedures were significantly more frequent in the non-split-dosage arm (21.2% vs 6.9%, odds ratio [OR] 3.60 [2.29-5.77], P < .0001). Independent predictors of poor bowel cleansing were male sex (OR 1.45 [1.08-1.96], P = .014) and a non-split-dosage bowel preparation schedule (OR 2.08 [1.89-2.37], P = .0001).
CONCLUSION: Low-volume PEG plus ascorbic acid is as effective as high-volume PEG-electrolyte solution but has superior palatability. A split-dosage schedule is the most effective bowel cleansing method. Colonoscopy should be performed within 8 hours of the last fluid intake. Copyright 2010 American Society for Gastrointestinal Endoscopy. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20561621     DOI: 10.1016/j.gie.2010.02.048

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  58 in total

1.  Improving the quality of bowel preparation: one step closer to the holy grail?

Authors:  Edward W Holt; Michael S Verhille
Journal:  Dig Dis Sci       Date:  2011-02       Impact factor: 3.199

2.  A randomized controlled trial comparing polyethylene glycol + ascorbic acid with sodium picosulphate + magnesium citrate solution for bowel cleansing prior to colonoscopy.

Authors:  S M Sahebally; J P Burke; S Chu; O Mabadeje; J Geoghegan
Journal:  Ir J Med Sci       Date:  2014-08-26       Impact factor: 1.568

3.  Bisacodyl plus split 2-L polyethylene glycol-citrate-simethicone improves quality of bowel preparation before screening colonoscopy.

Authors:  Flavio Valiante; Angelo Bellumat; Manuela De Bona; Michele De Boni
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

4.  Predictors of Inadequate Inpatient Colonoscopy Preparation and Its Association with Hospital Length of Stay and Costs.

Authors:  Rena Yadlapati; Elyse R Johnston; Dyanna L Gregory; Jody D Ciolino; Andrew Cooper; Rajesh N Keswani
Journal:  Dig Dis Sci       Date:  2015-06-21       Impact factor: 3.199

5.  Predicting Suboptimal Bowel Preparation: Taking It Up a PEG.

Authors:  Shaheel M Sahebally
Journal:  Dig Dis Sci       Date:  2016-11-23       Impact factor: 3.199

6.  An Automated Inpatient Split-dose Bowel Preparation System Improves Colonoscopy Quality and Reduces Repeat Procedures.

Authors:  Rena Yadlapati; Elyse R Johnston; Adam B Gluskin; Dyanna L Gregory; Rachel Cyrus; Lindsay Werth; Jody D Ciolino; David P Grande; Rajesh N Keswani
Journal:  J Clin Gastroenterol       Date:  2018-09       Impact factor: 3.062

7.  Split dose and MiraLAX-based purgatives to enhance bowel preparation quality becoming common recommendations in the US.

Authors:  Grace Clarke Hillyer; Benjamin Lebwohl; Corey H Basch; Charles E Basch; Fay Kastrinos; Beverly J Insel; Alfred I Neugut
Journal:  Therap Adv Gastroenterol       Date:  2013-01       Impact factor: 4.409

8.  A validated bowel-preparation tolerability questionnaire and assessment of three commonly used bowel-cleansing agents.

Authors:  I C Lawrance; R P Willert; K Murray
Journal:  Dig Dis Sci       Date:  2012-10-25       Impact factor: 3.199

9.  Same-day 2-L PEG-citrate-simethicone plus bisacodyl vs split 4-L PEG: Bowel cleansing for late-morning colonoscopy.

Authors:  Annalisa de Leone; Darina Tamayo; Giancarla Fiori; Davide Ravizza; Cristina Trovato; Giuseppe De Roberto; Linda Fazzini; Marco Dal Fante; Cristiano Crosta
Journal:  World J Gastrointest Endosc       Date:  2013-09-16

10.  Colonoscopy can miss diverticula of the left colon identified by barium enema.

Authors:  Ryota Niikura; Naoyoshi Nagata; Takuro Shimbo; Junichi Akiyama; Naomi Uemura
Journal:  World J Gastroenterol       Date:  2013-04-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.